Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer

Akhil Chawla*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


While the use of neoadjuvant therapy is well-accepted in the treatment of borderline resectable and locally advanced pancreatic cancers, the benefit of neoadjuvant chemotherapy in patients with resectable disease has been a topic of debate. Recently, key trials evaluating neoadjuvant chemotherapy for resectable pancreatic cancer have reported results. This review describes key clinical trials evaluating the use of preoperative therapy in patients with technically resectable pancreatic cancer with a focus on their contribution to the available evidence.

Original languageEnglish (US)
Pages (from-to)1423-1431
Number of pages9
JournalJournal of surgical oncology
Issue number6
StatePublished - May 1 2021


  • chemotherapy
  • neoadjuvant therapy
  • pancreatic cancer
  • resectable pancreatic cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer'. Together they form a unique fingerprint.

Cite this